Search results for "clinical significance"

showing 10 items of 207 documents

Bleaching efficacy of at home 16% carbamide peroxide. A long-term clinical follow-up study.

2019

OBJECTIVE To assess the whitening efficacy of a 16% carbamide peroxidase (CP) gel after 42 months of clinical follow-up. MATERIALS AND METHODS A retrospective clinical study was carried out involving 95 participants. CP 16% was applied for 90 minutes a day for 4 weeks using individualized trays. Tooth color was assessed using spectrophotometry at baseline, 1 week after the end of treatment, and every 6 months until completing 42 months of follow-up. Color parameters were compared using analysis of variance for repeated measures. The analysis by teeth groups was performed using two-way ANOVA. RESULTS The mean baseline L* was 81.7 ± 5.2 versus 83.6 ± 8.8 after 42 months (P<.01). L* showed a d…

0206 medical engineeringDentistryColor02 engineering and technologyCarbamide PeroxideRetrospective data03 medical and health sciences0302 clinical medicineTooth BleachingMedicineUreaClinical significanceTooth Bleaching AgentsGeneral DentistryRetrospective StudiesTooth whiteningbusiness.industryFollow up studiesRepeated measures design030206 dentistryHydrogen Peroxide020601 biomedical engineeringPeroxidesTooth colorAnalysis of varianceCarbamide peroxidebusinessFollow-Up StudiesJournal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]REFERENCES
researchProduct

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

2018

BACKGROUND Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice. OBJECTIVE To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 -antihistamine-refractory CSU in Germany. METHOD A World-wide Antihistamine-Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non-interventional study of CU in the real-world setting, supported by the manufacturer of omalizumab. Patie…

0301 basic medicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyMedizinDrug ResistanceOmalizumabOmalizumab03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineImmunology and AllergyHumansClinical significanceChronic UrticariaDisease burdenAngioedemabusiness.industryGuidelineDermatology Life Quality IndexMiddle Aged030104 developmental biology030228 respiratory systemHistamine H1 AntagonistsQuality of LifeAntihistamineFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases

2020

Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80&ndash

0301 basic medicineCancer Researchmedicine.medical_specialtyNeoplasm metastasisMetastasePrognoseContext (language use)lcsh:RC254-282AsymptomaticGastroenterologyArticle03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerbrain metastasesInternal medicineBrustkrebsasymptomaticMedicineClinical significanceddc:610Treatment outcomeHirnmetastasePerformance statusbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancer030104 developmental biologyRisk factorsOncologyLead time bias030220 oncology & carcinogenesisCohortBreast neoplasmsmedicine.symptombusinessDDC 610 / Medicine &amp; healthCancers
researchProduct

Potential benefits of colostrum in gastrointestinal diseases

2016

This paper reviews the composition of colostrum and the potential preventive and therapeutic use of this "first milk" for treating various gastrointestinal disorders in humans. Colostrum is a complex biological liquid that is richer in antimicrobial peptides, immune-regulating compounds and growth factors than the subsequent mature milk. The main functions of colostrum are to provide essential nutritional components, strengthen the natural defense system, modulate immune response, balance intestinal microbiota and enhance the growth and repair of several tissues. Several studies and clinical trials carried out both in vitro and in vivo on humans and animals suggest the clinical benefits of …

0301 basic medicineGastrointestinal Diseasesanimal diseasesAntimicrobial peptidesPhysiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesImmune systemfluids and secretionsImmunityIn vivogastrointestinal diseases dysbiosis colostrumMedicineAnimalsHumansClinical significanceColostrum Anti-Microbical Factors Immunity Growth Factors Intestinal Disorders ReviewGeneral Immunology and Microbiologybusiness.industryColostrumfood and beveragesmedicine.diseaseClinical trial030104 developmental biologyDietary SupplementsColostrumCattleFemalebusinessDysbiosis
researchProduct

Paroxysmal nocturnal haemoglobinuria: When delay in diagnosis and long therapy occurs

2017

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, caused by a somaticmutation in PIG-A gene that results in theabsence of CD55 and CD59, two important complement regulatory proteins. In thispaper, a case of PNH is retrospectively examined looking for clinical and laboratory features, and the entire course of the disease from the onset of the symptoms isdescribed, together with an adequate follow-up over a 7-years treatment period. Inthis case, the not specificity and the limited clinical relevance of the symptoms led to adelay in diagnosis. After thrombosis, Eculizumab therapy has been shown to be effec…

0301 basic medicineHemolytic anemiaPediatricsmedicine.medical_specialtyrenal failureParoxysmal nocturnal haemoglobinuriaparoxysmal nocturnal hemoglobinuriaCase ReportDiseaseCD5903 medical and health sciencesthrombotic eventshemic and lymphatic diseasesMedicineClinical significancebusiness.industrylcsh:RC633-647.5Bone marrow failureHematologylcsh:Diseases of the blood and blood-forming organsEculizumabEculizumabmedicine.diseaseThrombosisparoxysmal nocturnal hemoglo-binuria thrombotic events renal failure Eculizumab030104 developmental biologyParoxysmal nocturnal hemoglobinuriabusinessmedicine.drug
researchProduct

Myofilament function and body mass index.

2017

Body mass is reported to influence myocardial performance. Recent studies have emphasised the importance of negative inotropic adipocyte-derived factors and their impact on cardiac contractile function. However, the underlying mechanisms remain unclear. We aimed to determine whether body mass impacts cardiac force development on the level of the contractile apparatus. We examined the influence of body mass index (BMI) (3 groups: group I >25, group II 25–30, group III >30) on the myocardial performance of skinned muscle fibres. Right atrial tissue preparations of 70 patients undergoing aortocoronary bypass operation (CABG, 48 patients, group a) and aortic valve replacement (AVR, 22 patients,…

0301 basic medicineInotropeCardiac function curveMyofilamentmedicine.medical_specialtyobesitybody mass index030204 cardiovascular system & hematologyBiologyBioinformaticsGroup AcontractilityGeneral Biochemistry Genetics and Molecular BiologyContractility03 medical and health sciences0302 clinical medicineAortic valve replacementInternal medicinemedicineClinical significanceGeneral Pharmacology Toxicology and PharmaceuticsmyofilamentsGeneral Neuroscienceskinned fibersGeneral MedicineArticlesmedicine.disease030104 developmental biologyCardiologyBody mass indexBiomedical reports
researchProduct

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

2018

Background & aims AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon-free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort. Methods A retrospective analysis of the DHC-R (Deutsches Hepatitis C-Register, German Hepatitis C-Registry) coh…

0301 basic medicineLedipasvirMalemedicine.medical_specialtySofosbuvirSustained Virologic ResponseHepatitis C virusMedizinHepacivirusmedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineGermanyRibavirinMedicineHumansClinical significanceRegistriesRetrospective StudiesHepatitisFluorenesHepatologybusiness.industryRibavirinvirus diseasesHepatitis CViral Loadmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologychemistryRNA Viral030211 gastroenterology & hepatologyBenzimidazolesFemaleSofosbuvirbusinessUridine MonophosphateViral loadmedicine.drug
researchProduct

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

2019

Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- pati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisMesenchymalSurvivalALTlcsh:RC254-282digestive systemRisk Assessmentnot known03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicineGeneticsmedicineHumansClinical significanceALT; ATR; ATRX; Mesenchymal; Prognosis; Sarcoma; SurvivalProportional Hazards Modelsbusiness.industryHazard ratioSoft tissueTelomere HomeostasisSarcomaMiddle AgedTelomeremedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisSurvival Analysisdigestive system diseases3. Good health030104 developmental biologyATRATRXOncology030220 oncology & carcinogenesisRelative riskMeta-analysisSarcomabusinessResearch ArticleBMC Cancer
researchProduct

Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to …

2019

This study aims at clarifying the prognostic role of high-grade tumor budding (TB) in pancreatic ductal adenocarcinoma (PDAC) with the first systematic review and meta-analysis on this topic. Furthermore, we analyzed with a systematic review the relationship between TB and a recently suggested TB-associated mechanism: the epithelial to mesenchymal transition (EMT). Analyzing a total of 613 patients, 251 of them (40.9%) with high grade-TB, we found an increased risk of all-cause mortality (RR, 1.46; 95% CI, 1.13-1.88, p = 0.004; HR, 2.65; 95% CI, 1.79-3.91; p &lt; 0.0001) and of recurrence (RR, 1.61; 95% CI, 1.05-2.47, p = 0.03) for PDAC patients with high-grade TB. Moreover, we found that E…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPancreatic ductal adenocarcinomapancreatic cancerHigh grade tumorReviewEMT; budding; buds; epithelial to mesenchymal transition; pancreatic cancerbuddinglcsh:RC254-28203 medical and health sciences0302 clinical medicineTumor buddingPancreatic cancerInternal medicineMedicineClinical significanceEpithelial–mesenchymal transitionbusiness.industryEMTepithelial to mesenchymal transitionbudslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebud3. Good health030104 developmental biologyIncreased riskOncology030220 oncology & carcinogenesisMeta-analysisbusinessCancers
researchProduct

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

2021

About 10–20% of breast/ovarian (BC/OC) cancer patients undergoing germline BRCA1/2 genetic testing have been shown to harbor Variants of Uncertain Significance (VUSs). Since little is known about the prevalence of germline BRCA1/2 VUS in Southern Italy, our study aimed at describing the spectrum of these variants detected in BC/OC patients in order to improve the identification of potentially high-risk BRCA variants helpful in patient clinical management. Eight hundred and seventy-four BC or OC patients, enrolled from October 2016 to December 2020 at the “Sicilian Regional Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of University Hospital Policlini…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesGenomeGermlinegenetic testing03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerInternal medicinemedicineClinical significanceskin and connective tissue diseasesRC254-282Original ResearchGenetic testingAnamnesismedicine.diagnostic_testbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerBRCA1medicine.diseaseBRCA2ovarian cancer030104 developmental biologyOncology030220 oncology & carcinogenesisvariants of uncertain significance (VUS)Ovarian cancerbusinessFrontiers in Oncology
researchProduct